New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2014
08:50 EDTABIOARCA Biopharma prices $9M common stock and warrant offering
ARCA Biopharma announced that it has priced its previously announced public offering of common stock and warrants at a price of $1.70 for each share of common stock and a related warrant to purchase 0.25 shares of common stock, for gross proceeds of $8.7 million, prior to deducting underwriting discounts and commissions and offering expenses of the Company. Dawson James Securities, Inc. is acting as the sole book-running manager for the offering.
News For ABIO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 13, 2015
08:33 EDTABIOARCA Biopharma receives FDA fast track designation for Gencaro AF development
ARCA biopharma announced that the U.S. Food and Drug Administration has designated as a Fast Track development program the investigation of Gencaro for the prevention of atrial fibrillation/atrial flutter in a genetically modified heart failure population. Gencaro is the company’s investigational, pharmacologically unique beta-blocker and mild vasodilator. Gencaro is currently being evaluated as a potential treatment for atrial fibrillation in a genetically-defined heart failure population in GENETIC-AF, a Phase 2B/3 adaptive design clinical trial. ARCA anticipates that enrollment of approximately 200 patients in the Phase 2B portion of the trial will be completed by the end of 2016.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use